Show Menu

Organ Donation & Transplantation Cheat Sheet by

Adult Health 2


Who is a candi­dat­e?
Free of medical problems that would increase risk
- Will NOT take if: advanced/ uncorr­ected (cardiac) disease, cancer, psych issues, multiple organ involv­ement
Who is a donor?
Healthy, no infect­ion­/sy­stemic disease
May donate diseased organs (hepat­itis)
Living, NHBB, cadavers
No signif­icant cancer history
No history of kidney diseas­e/a­dequate kidney function
Human Leukocyte Antigen (HLA)
Same blood type, tissue type
Kidney: ages 2-70
Heart: <65yo, <1 yr to live, stages 3 & 4 HF

Factors to Consider

Tissue typing & blood typing
Body size


Extensive evaluation process - tissue typing
Health teaching - ready to take care of themse­lves?
Kidney transp­lant: dialysis after, may receive blood transf­usion before


Expected clinical findings & potential compli­cations MUST be antici­pated by the nurse!

Stages of Rejection

1. Hyperacute (& Accele­rated)
2. Acute
3. Chronic

Hyperacute Rejection

1st 48 hours - WORST
Recipient has antibody to donor transp­lant, not known before
Risk factors: previous transp­lant, different blood type
Clotting cascade vascular damage graft necrosis
A sure sign of graft failure
Symptoms: inc. BP & pain at site
- Matching HLA
- Start anti-r­eje­ction meds ASAP

Accele­rated Rejection

Within 1 week - 3 months
Variation of hyperacute
- Body makes lesser amount of antibodies
Specific to kidneys
Symptoms: anuria, inc. BUN & creat., pain

Acute Rejection

Within 3 months - MOST COMMON
Responds best to - immu­nos­upp­ressive therapy
- Dec. urine/­anu­ria
- Temp. > 100oF
- Inc. BP
- Inc. BUN & creat.

Chronic Rejection

3 months - 1 year
Most likely a combin­ation of cell-m­ediated responses to circul­ating antibodies
- Inc. BUN & creat.
- Fati­gue
- Elec­trolyte imbala­nces
Treated conser­vat­ively

Other Compli­cations

Infe­ction - AMS, low-grade fevers, opport­unistic infections
Hema­tom­as/­abs­ces­ses &
fluid accumu­lation = wound compli­cations
Urinary tract compli­cat­ions

Mainte­nance Drug Therapy

Combin­ation of...
Cycl­osp­orine (Gengraf & Sandim­mun­e): stops the production of IL-2, which prevents activation of lympho­cytes involved in transplant rejection
Anti­-pr­oli­fer­ati­ves: inhibit something essential to DNA synthesis, preventing cell divisi­on/­act­ivating lympho­cytes
- Imuran (Azath­iop­rine)
- Cellcept (Mycop­hen­ola­te)
- Prograf (Tacro­lim­us)
- Rapamune (Sirol­imus)
Risk of... leukop­enia, thromb­ocy­top­enia, opport­unistic infection
Mono­clonal antibo­dies: target activation sites of T-lymp­hoc­ytes, increasing their elimin­ation
- Orth­oclone (OKT3)
- Zenapax (Dacli­zum­ab)
Risk of... SIRS, developing malign­ancies
Poly­clonal antibo­dies: derived from other animals, bind to and eliminate most T-lymp­hoc­ytes, stopping rejection
- Atgam (Antit­hym­ocyte globul­in)

Help Us Go Positive!

We offset our carbon usage with Ecologi. Click the link below to help us!

We offset our carbon footprint via Ecologi


No comments yet. Add yours below!

Add a Comment

Your Comment

Please enter your name.

    Please enter your email address

      Please enter your Comment.

          Related Cheat Sheets

          More Cheat Sheets by mkravatz